Join to View Full Profile
351 N. Sumneytown PikeGwynedd, PA 19454
Dr. Davis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am board certified in Medical Oncology and specialize in the treatment of genitourinary cancers. I believe strongly in a multidisciplinary approach to management as well as involving patients in decisions about their care.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2000 - 2003- University of ChicagoResidency, Internal Medicine, 1997 - 2000
McGovern Medical School at UTHealthClass of 1997
Certifications & Licensure
TN State Medical License 2018 - 2027
WI State Medical License 2003 - 2023
IL State Medical License 1997 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) Start of enrollment: 2025 Mar 11
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Start of enrollment: 2020 May 19
Publications & Presentations
PubMed
- Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the ...Albert Jang, Tanya Jindal, Ali Raza Khaki, Cindy Y Jiang, Omar Alhalabi
Clinical Genitourinary Cancer. 2026-03-01 - Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Matthew Davidsohn, Dory Freeman
Urologic Oncology. 2026-01-01 - Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.Cindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, Dimitra Rafailia Bakaloudi, Rafee Talukder
The Oncologist. 2025-11-11
Authored Content
- What’s New in GU Malignancy? Update from the 2019 ASCO MeetingJune 2019
Press Mentions
AUA 2019: Management Paradigms for Advanced nccRCC in the Modern EraMay 5th, 2019
Professional Memberships
- Member
- Member
- Member
- Member
- Society of Urologic OncologyMember
Industry Relationships
- Senior Principal Scientist, Clinical Research, Merck & Co.Early Bladder Program Development Team2023 - Present
- IDMC Chair, Janssen SunRise Trials2020 - 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
